The need and challenges for development of an Epstein-Barr virus vaccine.

[1]  R. Lucas,et al.  Epstein-Barr virus infection , 2012, Neurology.

[2]  H. Varmus,et al.  Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention , 2011, Science Translational Medicine.

[3]  J. Cohen,et al.  Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after Challenge , 2011, PLoS pathogens.

[4]  Jaap M Middeldorp,et al.  A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation , 2009, Transplantation.

[5]  M. Moutschen,et al.  Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. , 2007, The Journal of infectious diseases.

[6]  Andreas Suhrbier,et al.  Phase I Trial of a CD8+ T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis , 2007, Journal of Virology.

[7]  A. Rickinson,et al.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.

[8]  Yi Yu,et al.  Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma , 2007, British Journal of Cancer.

[9]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[10]  S. Hamilton-Dutoit,et al.  Characteristics of Hodgkin's lymphoma after infectious mononucleosis. , 2003, The New England journal of medicine.

[11]  P. Rivailler,et al.  Complete Nucleotide Sequence of the Rhesus Lymphocryptovirus: Genetic Validation for an Epstein-Barr Virus Animal Model , 2002, Journal of Virology.

[12]  C. J. Chen,et al.  Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. , 2001, The New England journal of medicine.

[13]  R. Johnson,et al.  An animal model for acute and persistent Epstein-Barr virus infection. , 1997, Science.

[14]  T. Osato,et al.  Epstein-Barr virus and gastric carcinoma. , 1996, Seminars in cancer biology.

[15]  W. Schleif,et al.  Vero cell‐expressed Epstein‐Barr virus (EBV) gp350/220 protects marmosets from EBV challenge , 1989, Journal of medical virology.

[16]  M. Epstein,et al.  Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccine , 1985, Nature.

[17]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .

[18]  H. Balfour,et al.  Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. , 2013, The Journal of infectious diseases.

[19]  A. Evans,et al.  Epstein—Barr Virus and Malignant Lymphomas , 1997 .

[20]  C. Chu,et al.  First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. , 1995, Developments in biological standardization.